Paolo Pucci's Insider Trades & SAST Disclosures
Paolo Pucci's most recent trade in West Pharmaceutical Services, Inc. was a trade of 1,071 Common Stock done . Disclosure was reported to the exchange on May 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Paolo Pucci.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| West Pharmaceutical Servic... | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 1,071 | 10,946 (0%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 32,000 | 32,000 | - | - | Stock Option (right to buy) | |
| Merus N.V | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 8,844 | 8,844 | - | - | Share Option (right to buy) | |
| West Pharmaceutical Servic... | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Apr 2024 | 564 | 9,875 (0%) | 0% | 0 | Common Stock | |
| Replimune Group Inc | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 32,000 | 32,000 | - | - | Stock Option (right to buy) | |
| Merus N.V | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 14,414 | 14,414 | - | - | Share option (right to buy) | |
| West Pharmaceutical Servic... | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2023 | 616 | 9,311 (0%) | 0% | - | Common Stock | |
| Replimune Group Inc | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 25,200 | 25,200 | - | - | Stock Option (right to buy) | |
| Merus N.V | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2022 | 16,604 | 16,604 | - | - | Share option (right to buy) | |
| West Pharmaceutical Servic... | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 632 | 8,695 (0%) | 0% | - | Common Stock | |
| Replimune Group Inc | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 16,500 | 16,500 | - | - | Stock Option (right to buy) | |
| Merus N.V | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 May 2021 | 6,120 | 6,120 | - | - | Share option (right to buy) | |
| West Pharmaceutical Servic... | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 May 2021 | 577 | 8,063 (0%) | 0% | - | Common Stock | |
| Replimune Group Inc | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2021 | 16,500 | 16,500 | - | - | Stock Option (right to buy) | |
| Merus N.V | Paolo Pucci | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2020 | 17,262 | 17,262 | - | - | Share Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges